Becton, Dickinson and Company (BD), a medical device company, has invested $4.5m (€3.5m) in a syringe production plant in Ireland.
The company has made the investment on new equipment to boost the production of insulin pen needles, lancet blood sampling devices along with BD's Posiflush syringes, a prefilled saline and heparin lock flush hypodermic, reports Outsourcing-pharma.com.
The investment will create additional 28 jobs at the facility.
BD Ireland Diabetes Care Manufacturing director Cormac Reynolds was quoted by the website as saying, "This investment in Drogheda is part of the company's investment strategy for Ireland, which has also seen more than €34m invested in the company's other plant in Dun Laoghaire, Co Dublin."
Welcoming the investment news, Ireland's Industrial Development Authority (IDA) CEO Barry O'Leary said, "Continuous innovation by companies is vital in order to stay competitive - what BD has done here in Drogheda is a prime example of this."
